Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) had its price objective lifted by investment analysts at Robert W. Baird from $32.00 to $40.00 in a research note issued on Friday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Robert W. Baird's price target indicates a potential upside of 64.20% from the stock's previous close.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Enliven Therapeutics Trading Down 2.2 %

Shares of Enliven Therapeutics stock traded down $0.56 during trading hours on Friday, reaching $24.36. 165,583 shares of the company's stock were exchanged, compared to its average volume of 259,882. The company has a 50 day moving average of $26.16 and a two-hundred day moving average of $23.88. The stock has a market cap of $1.15 billion, a P/E ratio of -13.12 and a beta of 1.08. Enliven Therapeutics has a fifty-two week low of $9.80 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.17. As a group, analysts expect that Enliven Therapeutics will post -1.98 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,250 shares of the firm's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $28.56, for a total transaction of $178,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Joseph P. Lyssikatos sold 37,878 shares of Enliven Therapeutics stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $28.16, for a total transaction of $1,066,644.48. Following the completion of the sale, the insider now owns 1,016,035 shares in the company, valued at approximately $28,611,545.60. This represents a 3.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 152,195 shares of company stock valued at $4,091,454 in the last three months. 29.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ELVN. Quest Partners LLC boosted its holdings in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock worth $37,000 after buying an additional 742 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Enliven Therapeutics by 12.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock worth $668,000 after acquiring an additional 2,944 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Enliven Therapeutics by 25.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company's stock valued at $441,000 after acquiring an additional 3,518 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock worth $232,000 after purchasing an additional 3,559 shares during the period. Finally, American Century Companies Inc. boosted its position in Enliven Therapeutics by 44.7% during the second quarter. American Century Companies Inc. now owns 27,651 shares of the company's stock worth $646,000 after purchasing an additional 8,540 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.